ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Cost-Effectiveness of Protocol Biopsies in Kidney Transplantation

C. M. Puttarajappa, S. Hariharan, K. J. Smith

Medicine, University of Pittsburgh, Pittsburgh, PA

Meeting: 2020 American Transplant Congress

Abstract number: 617

Keywords: Economics, Protocol biopsy, Rejection

Session Information

Session Name: Biomarkers, Immune Assessment and Clinical Outcomes VI

Session Type: Oral Abstract Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:45pm

 Presentation Time: 3:15pm-3:27pm

Location: Virtual

*Purpose: To perform an economic evaluation of protocol biopsies in kidney transplantation

*Methods: We used a Markov decision analytical model (Figure 1) to compare the following strategies for detecting sub-clinical rejection (SCR) in the first year after kidney transplantation (KT): no protocol biopsy (PB), PB at 3 months, PB at 12 months, PB at 3 and 12 months and PB at 3, 6 and 12 months. Costs, utilities and probabilities were derived from published reports (select base case values are shown in the table). Key model inputs and assumptions were: 1) Both sub-clinical T-cell mediated rejection (SC-TCMR) and sub-clinical antibody mediated rejection (SC-ABMR) were included 2) All SCR episodes were treated 3) 50% of SCR occurred between 0 and 3 months and 50% occurred between 3 and 12 months after KT. 4) Biopsy had 100% sensitivity and specificity for detecting SCR. A lifetime analysis was performed. Incremental cost effectiveness ratios (ICERs) were calculated for each strategy, and one-way sensitivity analysis were performed.

*Results: On base case analysis, ICER for 12-month PB over no PB was $37,660 per quality adjusted life year (QALY) gained. 3-month PB yielded lower QALYs than 12-month PB at higher cost. QALY gains from increasing PB frequency during first year were small and resulted in high ICERs ($186,862 for PB at 3 and 12 months, and $272,978 for PB at 3,6 and 12 months). Table 3 shows the results of one-way sensitivity analysis of PB at 12 months over a no PB strategy. Results were most sensitive to patient age, and relative risk (RR) for graft failure from SC-TCMR and SC-ABMR. Cost-effectiveness worsened with increasing patient age and lower RR for graft failure from SC-TCMR and SC-ABMR. Results were also sensitive to biopsy cost, prevalence of SCR, and SCR treatment efficacy.

*Conclusions: In kidney transplantation, protocol biopsy more than once during the first year is not economically reasonable. Cost-effectiveness varied significantly with age, biopsy cost, SCR treatment efficacy, and SCR impact on graft survival.

 border=

Base case values for variables, and one-way sensitivity analysis for PB at 12 months over no PB
Variable Base case value >$50,000 per QALY >$100,000 per QALY
Incidence of SC-TCMR at year 1 (%) 12 <7 —
Relative Risk of graft loss due to untreated SC-TCMR 1.3 <1.25 <1.1
Incidence of SC-ABMR at year 1 (%) 3 <2 —
Relative Risk of graft loss due to untreated SC-ABMR 3 <2.2 <1.3
Probability of SC-TCMR treatment failure 0.3 >0.5 >0.8
Probability of SC-ABMR treatment failure 0.5 >0.65 >0.8
Cost of kidney transplant biopsy (US $) 1500 >1900 >3600
  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Puttarajappa CM, Hariharan S, Smith KJ. Cost-Effectiveness of Protocol Biopsies in Kidney Transplantation [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/cost-effectiveness-of-protocol-biopsies-in-kidney-transplantation/. Accessed May 11, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences